Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration in Healthy Volunteers
AstraZeneca AB
healthy volunteers
1 trial -
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis
Hoffmann-La Roche
Multiple Sclerosis (MS)
1 trial -
A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS
Alfasigma S.p.A.
chronic intestinal pseudo-obstruction (CIPO)
1 trial -
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Dr. Falk Pharma GmbH
Idiopathic or diabetic gastroparesis
1 trial -
A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.
Teva Pharma GmbH
Influenza
1 trial -
A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.
Teva Pharma GmbH
Pneumococcal infection
1 trial -
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24
Lacuna Pharma Pty Ltd
healthy male subjects
1 trial -
A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.
s.r.o.
high blood pressure
1 trial -
A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants
Lacuna Pharma Pty Ltd
Not applicable, healthy volunteers
1 trial -
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma
AbbVie Deutschland GmbH & Co. KG
Relapsed or Refractory Multiple Myeloma (R/R MM)
1 trial -
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS
Lacuna Pharma Pty Ltd
Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.
1 trial -
AVN-944 capsules for oral administration
Vertex Pharmaceuticals (Australia) Pty.
Acute Leukemia
1 trial -
Administration of UI087
United Therapeutics Europe Ltd
Diabetes Mellitus (Type 2)
1 trial -
Administration of the malaria inoculum
CNS Pharmaceuticals
Malaria
1 trial -
An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants
Lacuna Pharma Pty Ltd
Helicobacter pylori infection, GERD
1 trial -
BMN 111 administration via Injector Pen
BioMarin Pharmaceutical Australia Pty Ltd
Achondroplasia
1 trial -
Bioavailability study of stiripentol after single oral administration of two different formulations (capsule and oral suspension) in 24 healthy subjects
Biocodex
Dravet syndrome
1 trial -
Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
Laboratorios Tillomed Spain S.L.U
Diabetes
1 trial -
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
Orion Laboratories Pty.
short-term treatment of insomnia
1 trial -
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
Helsinn Birex Pharmaceuticals
Healthy volunteers
1 trial -
Coadministration of GA2 Sporozoites With Adjuvants (CoGA)
Disc Medicine
Falciparum malaria
1 trial -
DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS
Lacuna Pharma Pty Ltd
Hypolactasia
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources